Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of SYS6010 plus enlonstobart versus immunotherapy plus platinum-based chemotherapy as first-line treatment for PD-L1-positive advanced non-small cell lung cancer
CTR20262368Phase 3Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CPO301, PBI-1308 in non-small cell lung cancer (NSCLC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Jul 2026; status: active.
02
Drugs
CPO301PBI-1308
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262368.